{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:11:57Z","timestamp":1782983517752,"version":"3.54.5"},"reference-count":135,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.eprac.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:24:56Z","timestamp":1745839496000},"page":"946-955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Menopause in Cystic Fibrosis: Special Considerations for Bone Health, Menopausal Symptoms, and Treatment"],"prefix":"10.1016","volume":"31","author":[{"given":"Sarah","family":"Haroon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Sufian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim M.","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-8954","authenticated-orcid":false,"given":"Melissa S.","family":"Putman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2025.04.011_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.eprac.2025.04.011_bib2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.eprac.2025.04.011_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.eprac.2025.04.011_bib5","article-title":"Aging with CF: characteristics of people with CF aged 40 and older in the United States","author":"Ostrenga","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.011_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: a review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.011_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/GME.0000000000002386","article-title":"Sleep disturbance associated with the menopause","volume":"31","author":"Maki","year":"2024","journal-title":"Menopause"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.011_bib8","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1210\/jc.2012-4113","article-title":"Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity","volume":"98","author":"Sowers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"10.1016\/j.eprac.2025.04.011_bib9","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American heart association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2025.04.011_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.atherosclerosis.2016.10.005","article-title":"Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause","volume":"254","author":"Lobo","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.eprac.2025.04.011_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.maturitas.2023.107898","article-title":"Body composition analysis: a snapshot across the perimenopause","volume":"180","author":"Karaflou","year":"2024","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jcsm.12547","article-title":"Muscle and bone mass in middle-aged women: role of menopausal status and physical activity","volume":"11","author":"Sipil\u00e4","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/GME.0000000000002155","article-title":"Menopause in people with cystic fibrosis","volume":"30","author":"Prochownik","year":"2023","journal-title":"Menopause N Y N"},{"key":"10.1016\/j.eprac.2025.04.011_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)01507-8","article-title":"669 Significant impact of menopause transition in UK women with cystic fibrosis (fwCF): a large-center study in the highly effective modulator therapy era","volume":"23","author":"Weitnauer","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/aje\/kws421","article-title":"Factors related to age at natural menopause: longitudinal analyses from SWAN","volume":"178","author":"Gold","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"9614","key":"10.1016\/j.eprac.2025.04.011_bib16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(08)60346-3","article-title":"Menopause","volume":"371","author":"Nelson","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/10398562231165439","article-title":"Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review","volume":"31","author":"Alblooshi","year":"2023","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.eprac.2025.04.011_bib18","first-page":"12","article-title":"Sleep in children and young adults with cystic fibrosis","volume":"46","author":"Fauroux","year":"2023","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcf.2021.04.016","article-title":"Cardiovascular complications in cystic fibrosis: a review of the literature","volume":"21","author":"Poore","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib20","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jcf.2021.11.013","article-title":"Acute ST-elevation myocardial infarction in two young women with cystic fibrosis and cystic fibrosis-related diabetes","volume":"21","author":"Thambuluru","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2025.04.011_bib21","article-title":"Coronary artery disease in patients with cystic fibrosis \u2013 a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"24","key":"10.1016\/j.eprac.2025.04.011_bib22","first-page":"S1569","article-title":"Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor","volume":"01790-9","author":"Ratti","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2025.04.011_bib24","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/S1569-1993(24)01506-6","article-title":"668 Fat mass increases and lean mass decreases during 24 months of CFTR modulator therapy","volume":"23","author":"Brown","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/nu14020310","article-title":"The relationship between body composition, dietary intake, physical activity, and pulmonary status in adolescents and adults with cystic fibrosis","volume":"14","author":"Scully","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.eprac.2025.04.011_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1471-2474-9-125","article-title":"Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients","volume":"9","author":"Papaioannou","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.eprac.2025.04.011_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/jbmr\/zjae139","article-title":"Longitudinal changes in BMD in adults with cystic fibrosis","author":"Jad","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.011_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10666","article-title":"Prevalence and risk factors for low bone mineral density in adults with cystic fibrosis","volume":"6","author":"Boyle","year":"2022","journal-title":"JBMR Plus"},{"key":"10.1016\/j.eprac.2025.04.011_bib31","series-title":"Annual data report","year":"2023"},{"key":"10.1016\/j.eprac.2025.04.011_bib32","series-title":"Vaincre la Mucoviscidose and French Institute for Demographic Studies (Ined) Paris","year":"2019"},{"key":"10.1016\/j.eprac.2025.04.011_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/jbmr\/zjae139","article-title":"Longitudinal changes in bone mineral density in adults with cystic fibrosis","author":"Jad","year":"2024","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.04.011_bib35","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/218691","article-title":"Vitamin d deficiency in cystic fibrosis","volume":"2010","author":"Hall","year":"2010","journal-title":"Int J Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.011_bib36","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1172\/JCI2865","article-title":"Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells","volume":"101","author":"DiMango","year":"1998","journal-title":"J Clin Invest"},{"issue":"3 Pt 1","key":"10.1016\/j.eprac.2025.04.011_bib37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1164\/ajrccm.162.3.9910118","article-title":"Bone density, body composition, and inflammatory status in cystic fibrosis","volume":"162","author":"Ionescu","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.011_bib38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/thx.2003.012047","article-title":"Inflammatory related changes in bone mineral content in adults with cystic fibrosis","volume":"59","author":"Haworth","year":"2004","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcf.2009.11.007","article-title":"Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis","volume":"9","author":"Shead","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2265.1987.tb00776.x","article-title":"Amenorrhoea in cystic fibrosis","volume":"26","author":"Stead","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.011_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080098","article-title":"Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease","volume":"8","author":"Stalvey","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bone.2004.05.021","article-title":"Severe osteopenia in CFTR-null mice","volume":"35","author":"Dif","year":"2004","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.011_bib43","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.ajpath.2012.01.039","article-title":"The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation","volume":"180","author":"Le Henaff","year":"2012","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcf.2010.05.001","article-title":"Osteopenia in cftr-deltaF508 mice","volume":"9","author":"Paradis","year":"2010","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib45","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jcf.2022.08.011","article-title":"Evaluation of an association between RANKL and OPG with bone disease in people with cystic fibrosis","volume":"22","author":"Abid","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2478\/ams-2013-0011","article-title":"Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis","volume":"58","author":"Ambroszkiewicz","year":"2013","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.eprac.2025.04.011_bib47","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201312-2144LE","article-title":"Cystic Fibrosis and Bone Disease: Defective Osteoblast Maturation with the F508del Mutation in Cystic Fibrosis Transmembrane Conductance Regulator","author":"Velard","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1677\/joe.0.1720387","article-title":"Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women","volume":"172","author":"Racho\u0144","year":"2002","journal-title":"J Endocrinol"},{"issue":"46","key":"10.1016\/j.eprac.2025.04.011_bib49","doi-asserted-by":"crossref","first-page":"28890","DOI":"10.1074\/jbc.271.46.28890","article-title":"Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production","volume":"271","author":"Kimble","year":"1996","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.eprac.2025.04.011_bib50","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI11066","article-title":"Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-\u03b1","volume":"106","author":"Cenci","year":"2000","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.011_bib51","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1359\/jbmr.2001.16.8.1416","article-title":"Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones","volume":"16","author":"Ikeda","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.011_bib52","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.eprac.2025.04.011_bib53","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib54","doi-asserted-by":"crossref","first-page":"e1248","DOI":"10.1210\/clinem\/dgaa890","article-title":"The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis","volume":"106","author":"Putman","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2025.04.011_bib56","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1016\/S1569-1993(24)01496-6","article-title":"658 Longitudinal changes in bone mineral density in adolescents and adults with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor\u2014results from the PROMISE study","volume":"23","author":"Kindler","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib57","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"Sermet-Gaudelus","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2025.04.011_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(15)30164-8","article-title":"ePS05.5 Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?","volume":"14","author":"Velard","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib59","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/jc.2004-1629","article-title":"Guide to bone health and disease in cystic fibrosis","volume":"90","author":"Aris","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.04.011_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"AMERICAN association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal OSTEOPOROSIS-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/JCD:7:1:1","article-title":"Official positions of the international society for clinical Densitometry","volume":"7","author":"Leib","year":"2004","journal-title":"J Clin Densitom"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.200307-1049OC","article-title":"Efficacy of alendronate in adults with cystic fibrosis with low bone density","volume":"169","author":"Aris","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib62","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1378\/chest.08-0608","article-title":"Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial)","volume":"134","author":"Papaioannou","year":"2008","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.011_bib63","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-2600(13)70064-X","article-title":"Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate","volume":"1","author":"Bianchi","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jcf.2011.07.007","article-title":"Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis","volume":"10","author":"Haworth","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib65","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1164\/ajrccm.162.3.2002051","article-title":"Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation","volume":"162","author":"Aris","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib66","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/thorax.56.4.314","article-title":"Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis","volume":"56","author":"Haworth","year":"2001","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib67","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2265.2008.03434.x","article-title":"Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF)","volume":"70","author":"Chapman","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"S28","key":"10.1016\/j.eprac.2025.04.011_bib68","first-page":"353","article-title":"Zoledronate therapy for decreased bone density in adults with cystic fibrosis","volume":"40","author":"Boyle","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2025.04.011_bib69","article-title":"Evaluation of teriparatide for treatment of osteoporosis in four patients with cystic fibrosis: a case series","volume":"2014","author":"Siwamogsatham","year":"2014","journal-title":"Case Rep Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjms.2022.04.018","article-title":"Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis","volume":"364","author":"Crow","year":"2022","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib72","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1210\/jc.2011-3050","article-title":"An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation","volume":"97","author":"Tangpricha","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib73","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1210\/jc.2008-2012","article-title":"Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light","volume":"94","author":"Khazai","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib74","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2015.07.004","article-title":"A randomized controlled trial of vitamin D replacement strategies in pediatric CF patients","volume":"15","author":"Simoneau","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"165","key":"10.1016\/j.eprac.2025.04.011_bib75","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0010-2022","article-title":"Physical activity and its correlates in people with cystic fibrosis: a systematic review","volume":"31","author":"Kinaupenne","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.eprac.2025.04.011_bib76","article-title":"Leisure time physical activity and bone mineral density preservation during the menopause transition and postmenopause: a longitudinal cohort analysis from the Study of Women\u2019s Health across the Nation (SWAN)","volume":"21","author":"Greendale","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.eprac.2025.04.011_bib77","series-title":"Diabetic Bone Disease: Basic and Translational Research and Clinical Applications","first-page":"45","article-title":"Fracture risk assessment in diabetes","author":"Leslie","year":"2016"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.011_bib78","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1002\/jbmr.1759","article-title":"Type 2 diabetes and bone","volume":"27","author":"Leslie","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib79","article-title":"Bisphosphonates preserve bone mineral density and suppress bone turnover markers in early menopausal women: a systematic review and meta analysis of randomized trials","volume":"7","author":"Ahadzadeh","year":"2023","journal-title":"JBMR Plus"},{"key":"10.1016\/j.eprac.2025.04.011_bib80","author":"Conwell"},{"key":"10.1016\/j.eprac.2025.04.011_bib81","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jcf.2017.07.007","article-title":"Cystic Fibrosis and gastroesophageal reflux disease","volume":"16","author":"Maqbool","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"9142","key":"10.1016\/j.eprac.2025.04.011_bib82","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(05)79826-3","article-title":"Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis","volume":"352","author":"Haworth","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.04.011_bib84","first-page":"148","article-title":"Hyperpharmacotherapy in ageing cystic fibrosis patients: the first report of an atypical hip fracture","volume":"16","author":"Al-Azzani","year":"2015","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib85","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture prevention with infrequent zoledronate in women 50 to 60 Years of age","volume":"392","author":"Bolland","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2025.04.011_bib86","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","author":"Delmas","year":"1997","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib87","first-page":"2197","article-title":"A comparison of the effects of raloxifene and estrogen on bone in postmenopausal Women1","volume":"85","author":"Prestwood","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.011_bib88","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib89","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.ajog.2004.04.042","article-title":"Predictors of hot flushes in postmenopausal women who receive raloxifene therapy","volume":"191","author":"Aldrighi","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.011_bib90","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib91","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/path.4753","article-title":"Overexpression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis","volume":"240","author":"Delion","year":"2016","journal-title":"J Pathol"},{"key":"10.1016\/j.eprac.2025.04.011_bib92","series-title":"Markers of osteoporosis in cystic fibrosis","author":"Jain","year":"2024"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib93","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib94","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1210\/jc.2016-3781","article-title":"Letter to the editor: severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report","volume":"102","author":"Trovas","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.011_bib95","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post Hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9077","key":"10.1016\/j.eprac.2025.04.011_bib97","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet Lond Engl"},{"issue":"20","key":"10.1016\/j.eprac.2025.04.011_bib98","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.04.011_bib99","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 Months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"10.1016\/j.eprac.2025.04.011_bib101","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"issue":"22","key":"10.1016\/j.eprac.2025.04.011_bib102","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.3390\/ijms20225525","article-title":"The regulation of bone metabolism and disorders by Wnt signaling","volume":"20","author":"Maeda","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"29","key":"10.1016\/j.eprac.2025.04.011_bib103","doi-asserted-by":"crossref","first-page":"18009","DOI":"10.1074\/jbc.M115.646208","article-title":"Increased NF-\u03baB activity and decreased wnt\/\u03b2-catenin signaling mediate reduced osteoblast differentiation and function in \u0394F508 cystic fibrosis transmembrane conductance regulator (CFTR) mice","volume":"290","author":"Le Henaff","year":"2015","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.eprac.2025.04.011_bib104","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.eprac.2025.04.011_bib105","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib106","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archinte.166.3.357","article-title":"Conjugated equine estrogens and coronary heart disease: the Women\u2019s Health Initiative","volume":"166","author":"Hsia","year":"2006","journal-title":"Arch Intern Med"},{"issue":"17","key":"10.1016\/j.eprac.2025.04.011_bib107","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.2022.18625","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US preventive services task force recommendation statement","volume":"328","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eprac.2025.04.011_bib108","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.3128","article-title":"Menopausal hormone therapy use among postmenopausal women","volume":"5","author":"Yang","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"12","key":"10.1016\/j.eprac.2025.04.011_bib109","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1089\/jwh.2014.4985","article-title":"Gender differences in outcomes of patients with cystic fibrosis","volume":"23","author":"Harness-Brumley","year":"2014","journal-title":"J Womens Health"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib110","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00475-2020","article-title":"Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes","volume":"7","author":"Lam","year":"2021","journal-title":"ERJ Open Res"},{"issue":"21","key":"10.1016\/j.eprac.2025.04.011_bib111","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMoa1106126","article-title":"Effect of estrogen on Pseudomonas mucoidy and exacerbations in cystic fibrosis","volume":"366","author":"Chotirmall","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.011_bib112","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1513\/AnnalsATS.202008-1064OC","article-title":"A prospective study of the effects of sex hormones on lung function and inflammation in women with cystic fibrosis","volume":"18","author":"Holtrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ppul.21566","article-title":"Venous thromboembolism in cystic fibrosis","volume":"47","author":"Takemoto","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.eprac.2025.04.011_bib115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.maturitas.2023.04.004","article-title":"Oral estradiol\/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens\/medroxyprogesterone acetate in real-world practice","volume":"172","author":"Panay","year":"2023","journal-title":"Maturitas"},{"issue":"8045","key":"10.1016\/j.eprac.2025.04.011_bib116","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen","volume":"2","author":"Meade","year":"1977","journal-title":"Lancet Lond Engl"},{"issue":"1 Suppl","key":"10.1016\/j.eprac.2025.04.011_bib117","first-page":"85","article-title":"Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen\/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel","volume":"28","author":"Sabra","year":"1983","journal-title":"J Reprod Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.011_bib118","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"issue":"9382","key":"10.1016\/j.eprac.2025.04.011_bib119","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib120","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1160\/TH06-10-0567","article-title":"Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?","volume":"97","author":"Brosnan","year":"2007","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib121","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/13697137.2020.1804545","article-title":"Lessons from KEEPS: the kronos early estrogen prevention study","volume":"24","author":"Miller","year":"2020","journal-title":"Climacteric"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.011_bib122","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking menopausal hormone therapy: for whom, what, when, and how long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.011_bib123","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause N Y N"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.011_bib124","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/healthcare4030042","article-title":"Association of mid-life changes in body size, body composition and obesity status with the menopausal transition","volume":"4","author":"Karvonen-Gutierrez","year":"2016","journal-title":"Healthcare"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.011_bib125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2025.04.011_bib126","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.413","article-title":"7522 effects of trikafta on bone mineral density and body composition in patients with cystic fibrosis","volume":"8","author":"Mon","year":"2024","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib127","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westh\u00f6lter","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.011_bib128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.04.011_bib129","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.mayocp.2017.08.004","article-title":"Weight gain in women at midlife: a concise review of the pathophysiology and strategies for management","volume":"92","author":"Kapoor","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"10204","key":"10.1016\/j.eprac.2025.04.011_bib130","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"The Lancet"},{"issue":"17","key":"10.1016\/j.eprac.2025.04.011_bib131","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.3390\/cancers15174244","article-title":"Cystic fibrosis and cancer: unraveling the complex role of CFTR gene in cancer susceptibility","volume":"15","author":"Parisi","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.011_bib132","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13023-023-02671-z","article-title":"Increasing incidence rate of breast cancer in cystic fibrosis - relationship between pathogenesis, oncogenesis and prediction of the treatment effect in the context of worse clinical outcome and prognosis of cystic fibrosis due to estrogens","volume":"18","author":"Stastna","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.011_bib133","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.011_bib134","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1210\/jc.2002-020727","article-title":"Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers","volume":"87","author":"Gallagher","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.011_bib135","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause Society","volume":"30","year":"2023","journal-title":"Menopause"},{"key":"10.1016\/j.eprac.2025.04.011_bib136","series-title":"Stop medicine if Signs and symptoms of liver injury occur - drug safety Communication","article-title":"FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause","year":"2024"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.011_bib137","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1210\/jc.2016-1271","article-title":"Compounded bioidentical hormones in endocrinology practice: an endocrine society scientific statement","volume":"101","author":"Santoro","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:20:57Z","timestamp":1778224857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25001296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":135,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1530891X25001296"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.04.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menopause in Cystic Fibrosis: Special Considerations for Bone Health, Menopausal Symptoms, and Treatment","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}